Insights into the potential of Sanguinarine as a promising therapeutic option for breast cancer

Biochem Pharmacol. 2023 Jun:212:115565. doi: 10.1016/j.bcp.2023.115565. Epub 2023 Apr 20.

Abstract

Breast cancer (BC) is one of the leading causes of cancer-related deaths in women worldwide. The tumor microenvironment (TME) plays a crucial role in the progression and metastasis of BC. A significant proportion of BC is characterized by a hypoxic TME, which contributes to the development of drug resistance and cancer recurrence. Sanguinarine (SAN), an isoquinoline alkaloid found in Papaver plants, has shown promise as an anticancer agent. The present review focuses on exploring the molecular mechanisms of hypoxic TME in BC and the potential of SAN as a therapeutic option. The review presents the current understanding of the hypoxic TME, its signaling pathways, and its impact on the progression of BC. Additionally, the review elaborates on the mechanisms of action of SAN in BC, including its effects on vital cellular processes such as proliferation, migration, drug resistance, and tumor-induced immune suppression. The review highlights the importance of addressing hypoxic TME in treating BC and the potential of SAN as a promising therapeutic option.

Keywords: Breast cancer; Hypoxia; Prognosis; Sanguinarine; Tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzophenanthridines / pharmacology
  • Benzophenanthridines / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Hypoxia
  • Isoquinolines / pharmacology
  • Isoquinolines / therapeutic use
  • Tumor Microenvironment

Substances

  • sanguinarine
  • Benzophenanthridines
  • Isoquinolines